ReviewGynecologic oncology reports2025
Non-bacterial thrombotic endocarditis in ovarian cancer: A systematic review.
Review in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-Bacterial Thrombotic Endocarditis (NBTE) is characterized by the formation of sterile vegetations on the heart valves, often due to an underlying hypercoagulable state in the setting of malignancy, inflammation, or autoimmune disease. NBTE is a rare condition with a reported incidence rate of between 0.9% and 1.6%. Among gynecologic malignancies, NBTE is predominantly observed in ovarian cancer. A comprehensive review of the literature was conducted to understand the association between NBTE and ovarian cancer. Methods: A search of PubMed/MEDLINE was conducted from database inception to January 2024 using terms related to "Non-Bacterial Thrombotic Endocarditis" and "Ovarian Cancer." Studies were included if they involved patients diagnosed with both NBTE and ovarian cancer and excluded if they did not report confirmed NBTE and ovarian cancer. Risk of bias was assessed using Mixed Methods Analysis Testing. Results: The search identified 15 patients from 14 case reports, all female, with an average age of 50.6. The most common presenting diagnosis was CVA (53%). Ovarian cancer was diagnosed before NBTE 57% of the time. Most patients (67%) had stage III or IV cancer. Metastases predominantly affected lymph nodes (40%), liver (40%), and the other ovary (20%). Malignancy was treated with chemotherapy in 63% of cases. Surgical resection was performed in 40% of cases. One patient underwent radiation therapy. Mortality rate was 40% in patients treated with chemotherapy and 100% in patients not receiving chemotherapy. NBTE predominantly affected the mitral valve (52.4%), followed by the aortic valve at (33.3%), and the tricuspid valve (14.3%). 80% of patients experienced organ infarct. Infarcts predominantly affected the brain (27.0%), spleen (27.0%), lung (8.1%), and heart (8.1%). NBTE was treated with anticoagulation in 54% of cases. All-cause mortality at study publication was 75%. Conclusions: NBTE is an important, and often overlooked, cause of mortality in ovarian cancer. Clinicians should maintain high clinical suspicion for NBTE in patients with ovarian cancer presenting with thromboembolic phenomena. REGISTRATION: This review was registered with PROSPERO under the ID number: CRD42024501301.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.